Schrödinger Appoints Gary Sender to its Board of Directors
August 05, 2019 at 07:00 am EDT
Share
Schrödinger announced the appointment of veteran pharmaceutical executive Gary Sender to its Board of Directors, as well as his appointment to Chair of the Audit Committee. Mr. Sender brings over 30 years of financial leadership experience, with a strong track record of success. He is currently serves as the Chief Financial Officer of Nabriva Therapeutics. In that role, he has raised over $200 million in equity and debt capital, and provided the financial support for the acquisition of a private antibiotics firm with a late-stage asset, among other accomplishments.
Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. The Company operates through two segments: Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor). Its software was used by researchers around the world at more than 1,760 academic institutions.